Dave is President and CEO of NeoTract, Inc., a medical device company focused on shifting the treatment paradigm in urology. Under his leadership, NeoTract received FDA De Novo clearance for the UroLift® System, a minimally invasive technology to treat symptoms of benign prostatic hyperplasia (BPH). He also led the company to achieve critical reimbursement milestones, including new CPT 1 codes, a New Tech APC code and a national coverage policy by Aetna for the UroLift System. Internationally, NeoTract has achieved positive NICE guidance for the UroLift System in the UK and a prosthesis code with payment for the UroLift implant in Australia.
Dave joined NeoTract in July 2011, bringing over 25 years of management experience in the medical device field with an emphasis in urology. Prior to NeoTract, Dave was Global Vice President; General Manager for the Coloplast Surgical Urology division. Dave began his career at Osbon Medical Systems. He is a former board member of the Urology Society of America, the American Lithotripsy Society and EMKinetics. Dave holds an MBA from Argosy University and a BA in Political Science from the University of West Georgia.